Related Experiment Video
Updated: Jul 15, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma
Takeo Nomura1, Wen-Chin Huang, Seongil Seo
1Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Purpose:
We previously reported that the biological functions of beta2-microglobulin include antigen presentation and oncogenic activity. In the current study we investigated the direct role of beta2-microglobulin in the regulation of human renal cell carcinoma cell growth and the possible apoptotic inducing effect of blocking the beta2-microglobulin signaling pathway using an anti-beta2-microglobulin neutralizing antibody.
Materials And Methods:
We examined the effects of recombinant beta2-microglobulin protein and anti-beta2-microglobulin antibody on renal cell carcinoma cell growth and apoptosis in vitro. To seek a molecular understanding of anti-beta2-microglobulin antibody induced apoptosis we analyzed alterations in the growth and survival signaling components in the phosphatidylinositol 3-kinase/Akt, extracellular signal-regulated kinase and c-jun N-terminal kinase mediated pathways using corresponding kinase inhibitors in SN12C cells.
Results:
Recombinant beta2-microglobulin protein increased the growth of the 3 human renal cell carcinoma cell lines SN12C, Caki-1 and ACHN in a dose and time dependent manner. Treatment of SN12C, Caki-1 and ACHN cells with an anti-beta2-microglobulin polyclonal antibody strongly suppressed the growth of these cells in vitro, also in a dose and time dependent manner. The addition of recombinant beta2-microglobulin protein or anti-beta2-microglobulin antibody increased or decreased, respectively, the anchorage independent growth of SN12C cells. The recombinant beta2-microglobulin protein accelerated cell growth via activating phosphatidylinositol 3-kinase/Akt and extracellular signal-regulated kinase, and induced the phosphorylation of Bcl-xL/Bcl-2-associated death promoter. However, treatment with anti-beta2-microglobulin antibody induced cell death by inhibiting the phosphorylation of Akt and extracellular signal-regulated kinase, and activating c-jun N-terminal kinase, resulting in the induction of phosphorylation of B-cell lymphoma 2 and decreased phosphorylation of Bcl-xL/Bcl-2-associated death promoter, leading to apoptosis.
Conclusions:
Our results demonstrate that beta2-microglobulin has an important role in regulating the growth and survival of renal cell carcinoma cells and anti-beta2-microglobulin antibody offers a potential novel therapy for the treatment of human renal cell carcinoma.
Insights
Beta2-microglobulin promotes renal cell carcinoma growth. Blocking this protein with an anti-beta2-microglobulin antibody inhibits cancer cell proliferation and induces apoptosis, suggesting a novel therapeutic strategy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Beta2-microglobulin (B2M) is known to be involved in antigen presentation and oncogenesis.
- Its direct role in regulating human renal cell carcinoma (RCC) cell growth requires further investigation.
Purpose of the Study:
- To investigate the direct role of beta2-microglobulin in human renal cell carcinoma cell growth.
- To evaluate the potential of blocking beta2-microglobulin signaling with a neutralizing antibody to induce apoptosis in RCC cells.
Main Methods:
- In vitro assessment of recombinant beta2-microglobulin protein and anti-beta2-microglobulin antibody effects on RCC cell lines (SN12C, Caki-1, ACHN).
- Analysis of signaling pathways including PI3K/Akt, ERK, and JNK using kinase inhibitors to understand the molecular mechanisms of antibody-induced apoptosis.
Main Results:
- Recombinant beta2-microglobulin protein dose-dependently increased RCC cell growth and anchorage-independent growth.
- Anti-beta2-microglobulin antibody significantly suppressed RCC cell growth and anchorage-independent growth in vitro.
- Antibody treatment inhibited Akt and ERK phosphorylation, activated JNK, and modulated Bcl-xL/BAD phosphorylation, leading to apoptosis.
Conclusions:
- Beta2-microglobulin plays a significant role in regulating the growth and survival of renal cell carcinoma cells.
- Anti-beta2-microglobulin antibody demonstrates potential as a novel therapeutic agent for human renal cell carcinoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...